Facebook Linkedin RSS Twitter Youtube
Home 2024

lilly

StockWatch: BioAge, Orum Reflect Renewed Interest in IPOs
Drug Discovery

StockWatch: BioAge, Orum Reflect Renewed Interest in IPOs

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration
Drug Discovery

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk
Drug Discovery

StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data
Drug Discovery

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs
Drug Discovery

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs

Lilly to Acquire DICE for $2.4B, Expanding Immunology Pipeline
Drug Discovery

Lilly to Acquire DICE for $2.4B, Expanding Immunology Pipeline

Servier and miRagen Sign $352M Deal for Cardiovascular miRNA Therapeutics
News

Servier and miRagen Sign $352M Deal for Cardiovascular miRNA Therapeutics

Seattle and Millennium Report 75% Response Rate in Pivotal ADC Hodgkin Lymphoma Trial
Cancer

Seattle and Millennium Report 75% Response Rate in Pivotal ADC Hodgkin Lymphoma Trial

Eisai and Quintiles to Jointly Develop Six Eisai Anticancer Agents
Cancer

Eisai and Quintiles to Jointly Develop Six Eisai Anticancer Agents

Transave and NIAID to Evaluate Antibiotic for Nontuberculous Mycobacteria Lung Infections
Drug Discovery

Transave and NIAID to Evaluate Antibiotic for Nontuberculous Mycobacteria Lung Infections

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.